APSD of Nasal Products

Nasal drug products typically produce droplets larger than 10-20 microns, to ensure nasal deposition and minimise deposition within the lungs. However, a proportion of fine droplets in the <10 micron range may also be produced. Deposition of this respirable fraction beyond the nasal tract may be undesirable and must be quantified. Aerodynamic particle sizing with a cascade impactor is a US FDA requirement and is recommended in USP <601> to assess potential deposition beyond the nasal cavity.

Our nasal product testing solutions enable better, more informative testing in line with evolving market requirements.

Nasal Sprays
Nasal Aerosols
Nasal Powders
Nasal Sprays
Nasal Aerosols
Nasal Powders

Please select an option:

Next Generation Impactor (NGI) Andersen Cascade Impactor (ACI) Glass Twin Impinger (GTI)
Learn More

Please select an option:

Next Generation Impactor (NGI) Andersen Cascade Impactor (ACI) Glass Twin Impinger (GTI)
Learn More

Please select an option:

Next Generation Impactor (NGI) Andersen Cascade Impactor (ACI) Glass Twin Impinger (GTI)
Learn More

Related Services

Training

Training

We offer a range of training courses, presentations and seminars covering a wide range of topics.

Find Out More
Training

Servicing

A comprehensive range of both in-house and on-site product servicing options are available

Find Out More
Training

Support

Our team of experienced technicians and engineers are on hand to help and advise

Find Out More

Related News & Resources

Alberta Idealised Nasal Inlet AINI with Next Generation Impactor NGI

New IPAC-RS paper offers insight and guidance for testing aqueous nasal inhalation products

02 November 2023; Nottingham, UK: A new paper from the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) provides valuable insight on laboratory…

Find Out More

Copley introduces the new Flow Rate Sensor, a dedicated device for inhaler testing systems.

27 June 2023; Nottingham, UK: The new Flow Rate Sensor FRS is the latest addition to Copley Scientific’s orally inhaled and nasal drug product…

Find Out More
gentle rocker

Introducing the Copley Impactor Genie™ IG 200i, a two-in-one solution for quicker, more efficient inhaled product testing

25th April 2023; Nottingham, UK: The new Impactor Genie™ IG 200i from Copley Scientific is a cost- and space-efficient semi-automation tool for regulatory and…

Find Out More

Copley launches EnviroMate™, an efficient, benchtop environmental chamber for inhaler testing

14 September 2022; Nottingham, UK: EnviroMate™ is a benchtop environmental control chamber from Copley, the world’s leading manufacturer and supplier of inhaler testing equipment,…

Find Out More

New accessory completes Copley’s solution for automated nasal drug product testing

26 October 2021; Nottingham, UK: The latest accessory from Copley Scientific, the global leader in inhaled product testing equipment, simplifies the measurement of delivered…

Find Out More
We support the Taskforce plan for Lung Health

Copley Scientific joins the Industries Forum of the Taskforce for Lung Health

23 June 2021; Nottingham, UK: Copley Scientific has joined the Industries Forum of the Taskforce for Lung Health. The Taskforce is a collaboration of over…

Find Out More
Inhalytix - Run Comparison

Introducing Inhalytix®: a new solution for analysing and managing inhaler test data from Copley

18 March 2021; Nottingham, UK: Inhalytix® is a completely new software solution from Copley, the global leader in inhaler testing equipment, that brings a…

Find Out More

Copley introduces a comprehensive range for nasal product testing

11 March 2021, Nottingham, UK: Copley Scientific, the global leader in OINDP testing equipment, has introduced a series of new accessories that work with…

Find Out More

Nasal Product Testing Brochure 2023 (2 mb)

Find Out More

ONdrugDelivery Article: November 2023

Perfect Timing for the Automation of OINDP Testing In this article, Adam Smith, Product Manager – Automation, and Clair Brooks, PhD, Applications Specialist, both…

Find Out More

PMPS Q&A (Samedan): April 2023

Nasal Drug Product Development Matthew Fenn, Head of Business Development, sat down with PMPS Magazine to discuss the topic of nasal drug testing and…

Find Out More

Q&A: OINDPnews 2022

Reducing Inhaler Testing Variability Through Test Environment Control In this Q&A with OINDPnews, our CEO Mark Copley answers questions about the importance of the…

Find Out More

RDD 2022 Poster: Chen et al.

In Vitro Regional Deposition of Nasal Sprays in an Idealized Nasal Inlet: Comparison with In Vivo Gamma Scintigraphy John Z. Chen, Warren H. Finlay…

Find Out More

Manufacturing Chemist Feature: July 2021

Refining Test Methods for a New Generation of Nasal Drug Products The nasal drug product market is currently the focus of considerable research activity….

Find Out More

DDD 2021 Respiratory eBook Profile

Semi-Automating Inhaler Testing – A Good Idea, but Where to Start? Cascade impaction is a vital technique in the development and manufacture of orally…

Find Out More

Microbioz India: February 2021

A short Q&A with our CEO, Mark Copley, on inhaled product testing

Find Out More